EP4623925A3 - Peptide compositions and methods of use - Google Patents

Peptide compositions and methods of use

Info

Publication number
EP4623925A3
EP4623925A3 EP25186051.6A EP25186051A EP4623925A3 EP 4623925 A3 EP4623925 A3 EP 4623925A3 EP 25186051 A EP25186051 A EP 25186051A EP 4623925 A3 EP4623925 A3 EP 4623925A3
Authority
EP
European Patent Office
Prior art keywords
methods
peptide compositions
photoreceptors
fas
trail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP25186051.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4623925A2 (en
Inventor
Cagri G. BESIRLI
Alexander J BRIDGES
John K. FRESHLEY
William A. Hunke
Linda L JOHNSON
Francis X SMITH
Ethan SYLVAIN
David N. ZACKS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
ONL Therapeutics Inc
Original Assignee
University of Michigan System
ONL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, ONL Therapeutics Inc filed Critical University of Michigan System
Publication of EP4623925A2 publication Critical patent/EP4623925A2/en
Publication of EP4623925A3 publication Critical patent/EP4623925A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP25186051.6A 2015-05-01 2016-04-29 Peptide compositions and methods of use Pending EP4623925A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
EP21200594.6A EP3997981A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use
EP16789830.3A EP3288379B1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP21200594.6A Division EP3997981A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use
EP16789830.3A Division EP3288379B1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (2)

Publication Number Publication Date
EP4623925A2 EP4623925A2 (en) 2025-10-01
EP4623925A3 true EP4623925A3 (en) 2026-02-11

Family

ID=57217771

Family Applications (3)

Application Number Title Priority Date Filing Date
EP25186051.6A Pending EP4623925A3 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use
EP16789830.3A Active EP3288379B1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use
EP21200594.6A Withdrawn EP3997981A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP16789830.3A Active EP3288379B1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use
EP21200594.6A Withdrawn EP3997981A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Country Status (21)

Country Link
US (5) US10508134B2 (https=)
EP (3) EP4623925A3 (https=)
JP (2) JP6884755B2 (https=)
KR (2) KR20240046280A (https=)
CN (2) CN113651873B (https=)
AU (1) AU2016258837B2 (https=)
CA (1) CA2984154A1 (https=)
CY (1) CY1124911T1 (https=)
DK (1) DK3288379T3 (https=)
EA (2) EA035293B1 (https=)
ES (1) ES2906173T3 (https=)
HR (1) HRP20220138T1 (https=)
HU (1) HUE057883T2 (https=)
LT (1) LT3288379T (https=)
MX (1) MX387317B (https=)
PL (1) PL3288379T3 (https=)
PT (1) PT3288379T (https=)
RS (1) RS62866B1 (https=)
SI (1) SI3288379T1 (https=)
SM (1) SMT202200069T1 (https=)
WO (1) WO2016178993A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
US20230094423A1 (en) * 2019-12-18 2023-03-30 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor
EP4355349A4 (en) * 2021-06-15 2025-04-16 ONL Therapeutics, Inc. Methods and compositions for treating eye diseases and disorders
AU2022311780A1 (en) * 2021-07-13 2024-02-08 Onl Therapeutics, Inc. Methods and compositions for improving visual function in ocular diseases and disorders
EP4456908A4 (en) * 2021-12-27 2025-08-27 Onl Therapeutics Inc SFASL TO INHIBIT RPE CELL DEATH AND ASSOCIATED DISORDERS
EP4565596A1 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4565595A2 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4698204A1 (en) * 2023-04-19 2026-02-25 ONL Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
WO2007064997A2 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
US20100226878A1 (en) * 2009-03-03 2010-09-09 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
US20140371161A1 (en) * 2012-01-18 2014-12-18 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
CA2561809A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
EP1737483A2 (en) 2004-04-23 2007-01-03 University of Pittsburgh of the Commonwealth System of Higher Education Cell death modulation via antagonists of fasl and fas activation
BRPI0609227A2 (pt) * 2005-05-10 2010-03-09 Alcon Inc composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
JP5529754B2 (ja) * 2007-12-21 2014-06-25 ストライカー コーポレイション Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体
WO2010113753A1 (ja) * 2009-03-30 2010-10-07 参天製薬株式会社 ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用
CN102574822A (zh) * 2009-08-04 2012-07-11 阿米拉制药公司 作为溶血磷脂酸受体拮抗剂的化合物
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
SG195302A1 (en) * 2011-06-06 2013-12-30 Kineta One Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
JP6087429B2 (ja) * 2012-06-21 2017-03-01 ハノル バイオファーマ カンパニー リミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
US20150265679A1 (en) * 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
US20180024145A1 (en) 2015-02-05 2018-01-25 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
US10508134B2 (en) * 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
JP7493334B2 (ja) 2016-07-05 2024-05-31 ユニバーシティ オブ マサチューセッツ 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達
AR112257A1 (es) 2017-06-21 2019-10-09 Gilead Sciences Inc Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
EP3768301A4 (en) 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
CN112566622A (zh) 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
WO2007064997A2 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
US20100226878A1 (en) * 2009-03-03 2010-09-09 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
US20140371161A1 (en) * 2012-01-18 2014-12-18 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAGRI G. BESIRLI ET AL: "Inhibition of Retinal Detachment-Induced Apoptosis in Photoreceptors by a Small Peptide Inhibitor of the Fas Receptor", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, vol. 51, no. 4, 1 April 2010 (2010-04-01), US, pages 2177, XP055506368, ISSN: 1552-5783, DOI: 10.1167/iovs.09-4439 *
KYUN-HWAN KIM ET AL: "Peptide amidation: Production of peptide hormones in vivo and in vitro", BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, 1 August 2001 (2001-08-01), Seoul, pages 244 - 251, XP055184890, Retrieved from the Internet <URL:http://search.proquest.com/docview/229459448> [retrieved on 20150422], DOI: 10.1007/BF02931985 *

Also Published As

Publication number Publication date
US11597749B2 (en) 2023-03-07
AU2016258837B2 (en) 2020-12-03
CA2984154A1 (en) 2016-11-10
EP3288379B1 (en) 2021-11-03
JP2021120400A (ja) 2021-08-19
DK3288379T3 (da) 2022-02-07
EP3997981A1 (en) 2022-05-18
KR20240046280A (ko) 2024-04-08
EP3288379A1 (en) 2018-03-07
EP4623925A2 (en) 2025-10-01
CY1124911T1 (el) 2023-01-05
US12258425B2 (en) 2025-03-25
CN107708416B (zh) 2021-06-29
US10829518B2 (en) 2020-11-10
MX387317B (es) 2025-03-18
JP6884755B2 (ja) 2021-06-09
US20210094985A1 (en) 2021-04-01
EA035293B1 (ru) 2020-05-26
HRP20220138T1 (hr) 2022-05-27
CN113651873B (zh) 2025-09-02
HUE057883T2 (hu) 2022-06-28
WO2016178993A1 (en) 2016-11-10
US20250346631A1 (en) 2025-11-13
EA202090184A3 (ru) 2020-07-31
AU2016258837A1 (en) 2017-11-09
EP3288379A4 (en) 2018-10-24
JP2018514590A (ja) 2018-06-07
PL3288379T3 (pl) 2022-03-07
SMT202200069T1 (it) 2022-03-21
CN113651873A (zh) 2021-11-16
RS62866B1 (sr) 2022-02-28
US20230287052A1 (en) 2023-09-14
MX2017014075A (es) 2018-07-06
KR20170140383A (ko) 2017-12-20
ES2906173T3 (es) 2022-04-13
BR112017023479A2 (pt) 2018-07-24
CN107708416A (zh) 2018-02-16
KR102652804B1 (ko) 2024-04-01
LT3288379T (lt) 2022-02-25
US20200123201A1 (en) 2020-04-23
US20180291062A1 (en) 2018-10-11
SI3288379T1 (sl) 2022-06-30
PT3288379T (pt) 2022-02-08
HK1251979A1 (zh) 2019-05-10
EA202090184A2 (ru) 2020-05-31
US10508134B2 (en) 2019-12-17
EA201792399A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
EP4623925A3 (en) Peptide compositions and methods of use
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
EP3665285A4 (en) PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR VIRUS ADMINISTRATION
EP3880690A4 (en) PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
WO2015009820A3 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
IL254617A0 (en) Improved assays for the potential of retinal pigment epithelium (rpe) cells and photoreceptor progenitors
UA114298C2 (uk) Пептид торк та вакцина, що його містить
WO2015149016A3 (en) Breast and ovarian cancer vaccines
HUE061877T2 (hu) Ciklosporin-analógok gyógyszerkészítményei
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
WO2016011201A3 (en) Epha4 cyclic peptide antagonists for neuroprotection and neural repair
NZ709983A (en) Nutritional compositions containing a peptide component and uses thereof
MX2017001649A (es) Peptido derivado de koc1 y vacuna que lo incluye.
EP3848383A3 (en) Urlc10-derived peptide and vaccine containing same
TN2015000129A1 (en) POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
MX2017001650A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
KR101646325B9 (ko) 해양 미세조류 스피루리나 속 소화가수분해물 및 이로부터 유래된 펩타이드를 유효성분으로 함유하는 고혈압 예방 및 치료용 조성물
HK40075110A (en) Adeno-associated virus vector pharmaceutical composition and methods
EP3755380A4 (en) COMPOSITIONS AND PROCEDURES FOR THE ADMINISTRATION AND EXPRESSION OF SMALL PEPTIDES INHIBITORS AND THEIR USE
HK40043675A (en) Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
HK40033334A (en) Peptides and nanoparticles for intracellular delivery of virus
HK1235280A1 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3997981

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3288379

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038000000

Ipc: A01N0025000000

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 25/00 20060101AFI20251014BHEP

Ipc: A61K 38/00 20060101ALI20251014BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 25/00 20060101AFI20260106BHEP

Ipc: A61K 38/00 20060101ALI20260106BHEP